# EDGAR Filing Document

**Accession Number:** 0001772028
**File Stem:** 0001354457-23-000151
**Filing Date:** 2023-3
**Character Count:** 6197
**Document Hash:** 29e3b67fe4fc8d03090f5ac5edd692d6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001354457-23-000151.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0001354457-23-000151

**CONFORMED SUBMISSION TYPE**: 25-NSE

**CONFIRMING COPY**: 

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230303

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scopus BioPharma Inc.
- **CENTRAL INDEX KEY:** 0001772028
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 821248020
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 25-NSE
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39788

**BUSINESS ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVENUE, SUITE 300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170
- **BUSINESS PHONE:** (212) 479-2513

**MAIL ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVENUE, SUITE 300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Scopus Biopharma Inc.
- **DATE OF NAME CHANGE:** 20190327
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nasdaq Stock Market LLC
- **CENTRAL INDEX KEY:** 0001354457
- **IRS NUMBER:** 521165937
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 25-NSE

**BUSINESS ADDRESS:**
- **STREET 1:** One Liberty Plaza
- **CITY:** New York
- **STATE:** NY
- **ZIP:** 10006
- **BUSINESS PHONE:** 301-978-4144

**MAIL ADDRESS:**
- **STREET 1:** Office of General Counsel
- **STREET 2:** 805 King Farm Blvd.
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** The Nasdaq Stock Market LLC
- **DATE OF NAME CHANGE:** 20060224

## Exhibit 99.25

```

Delisting Determination, The Nasdaq Stock Market, LLC,
March 3, 2023, Scopus BioPharma Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the common stock and warrant of Scopus BioPharma Inc.
(the Company), effective at the opening of the trading session on
March 13, 2023.
Based on review of information provided by the Company, Nasdaq
Staff determined that the Company no longer qualified for listing
on the Exchange pursuant to Listing Rule 5450(b)(2)(A). The
Company was notified of the Staff determination on July 13,
2022. On July 20, 2022, the Company exercised its right to appeal
the Staff determination to the Listing Qualifications Hearings
Panel (Panel) pursuant to Rule 5815. A Panel hearing was held on
August 25, 2022. On October August 31, 2022, Staff issued an
additional delist determination letter for the Company failure
to meet the requirements of Listing Rule 5450(b)(2)(C).
On September 13, 2022, upon review of the information provided
by the Company, the Panel determined to grant the Company request
to remain listed in the Exchange subject to a series of milestones.
After failing to meeting the Hearings Panel exception, on December
15, 2022, the Hearings Panel issued a final decision denying the
Company continued listing and notified the Company that trading in
the Company securities would be suspended on December 19, 2022.
The Company did not appeal the Panel decision to the Nasdaq Listing
and Hearing Review Council (Council) and the Council did not call
the matter for review. The Staff determination to delist the Company
became final on January 30, 2023.

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 25

### NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

**Commission File Number:** 001-39788

|  |  |
|:---|:---|
| Issuer:                                                                                                             | Scopus BioPharma Inc.                           |
| Exchange:                                                                                                           | Nasdaq Stock Market LLC                         |
| (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |  |
| Address:                                                                                                            | 420 Lexington Avenue, New York, NEW YORK, 10170 |
| Telephone number:                                                                                                   | 917-848-7963                                    |
| (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)   |  |
| (Description of class of securities)                                                                                | Common Stock                                    |

---

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- [ ] 17 CFR 240.12d2-2(a)(1)
- [ ] 17 CFR 240.12d2-2(a)(2)
- [ ] 17 CFR 240.12d2-2(a)(3)
- [ ] 17 CFR 240.12d2-2(a)(4)
- [x] Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
- [ ] Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

---

Pursuant to the requirements of the Securities Exchange Act of 1934, Nasdaq Stock Market
LLC certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing the Form 25 and has caused this notification to be signed on its
behalf by the undersigned duly authorized person.

| Date       | By   | Name          | Title            |
|:---|:---|:---|:---|
| 2023-03-03 |  | Aravind Menon | Hearings Advisor |

Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR
240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.